Logo

• Closed gynecological cancer (KGOG1023)

  Phase III randomized study of concurrent chemotherapy and pelvic radiation therapy with or without adjuvant chemotherapy in high-risk patients with early-stage cervical carcinoma following radical hysterectomy

  • PI / PI기관 Jae-Hoon Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-29
  • Current Enrollment / Estimated Enrollment 237 person / 235 person (100.89999999999999%)

• Closed gynecological cancer (KGOG1022)

  GOG-233: Utility of preoperative FDG-PET/CT scanning prior to primary chemoradiation therapy to detect retroperitoneal lymph node metastasis in patients with locoregionally advanced carcinoma of the cervix (IB2, IIA ≥4 CM, IIB-IVA) or endometrium (Grade 3 endometrioid endometrial carcinoma; serous papillary carcinoma, clear cell carcinoma, or carcinosarcoma (any grade); and Grade 1 or 2 endometriord endometrial carcinoma with cervical stromal involvement overt in clinical examination or confirmed by endocervical curettage)

  • PI / PI기관 Jae-Weon Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2022-05-10
  • Current Enrollment / Estimated Enrollment 384 person / 380 person (101.1%)

• Closed gynecological cancer (KGOG3038)

  MOCCA : A Multicentre Phase II randomised trial of Durvalumab (MEDI4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinomas

  • PI / PI기관 Kidong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-29
  • Current Enrollment / Estimated Enrollment 66 person / 46 person (143.5%)

• Finished gynecological cancer (KGOG2015S)

  Prediction of final pathology depending on preoperative myometrial invasion and grade assessment in women with low risk endometrial cancer: a KGOG2015 ancillary study

  • PI / PI기관 Banghyun Lee / 인하대병원(Inha University Hospital)()
  • Registration Date / Last Update Posted 2023-03-14 / 2024-09-04
  • Current Enrollment / Estimated Enrollment person / 0 person (0.0%)

• Finished gynecological cancer (KGOG4004)

  • PI / PI기관 이유영, 김명선 /
  • Registration Date / Last Update Posted 2022-05-10 / 2022-05-10
  • Current Enrollment / Estimated Enrollment 0 person / 80 person (0.0%)

• Finished gynecological cancer (KGOG3052)

  Retrospective-Progression free survival in women who received Bevacizumab vs. Olaparib Maintenance after 2nd line chemotherapy for BRCAm platinum sensitive recurrent ovarian cancer (BOM)

  • PI / PI기관 Kidong Kim /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 207 person / 100 person (206.99999999999997%)

• Finished gynecological cancer (KGOG3048R)

  Gonadotropin-releasing hormone (GnRH) agonist for prevention of chemotherapy induced menopause in malignant ovarian germ cell tumor: a multicenter study

  • PI / PI기관 Min Chul Choi /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 358 person / 300 person (119.30000000000001%)

• Finished gynecological cancer (KGOG3048)

  Gonadotropin-releasing hormone (GnRH) agonist for prevention of chemotherapy induced menopause in malignant ovarian germ cell tumor: a multicenter prospective study

  • PI / PI기관 Min Chul Choi /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 65 person / 65 person (100.0%)

• Finished gynecological cancer (KGOG3047)

  Nation-wide analysis of clinical NGS panel to perform precision oncology for epithelial ovarian, peritoneal and tubal cancer patient

  • PI / PI기관 Jeong-Won Lee /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 663 person / 300 person (221.0%)

• Finished gynecological cancer (KGOG3046)

  TRU-D: A phase II study of neoadjuvant chemotherapy plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage ovarian cancer

  • PI / PI기관 Jung-Yun Lee /
  • Registration Date / Last Update Posted 2022-05-10 / 2023-03-28
  • Current Enrollment / Estimated Enrollment 48 person / 48 person (100.0%)

* (사)대한부인종양연구회는 게시된 세부 임상연구 정보에 대해 법적 책임이 없습니다.